Shall we dive into a dangerous swing trade!
$AN2 Therapeutics(ANTX.US$ So lets start here! Im basing my in on the bottom. And Y’all know i really likes me some bottoms! Hehehe! This just touched 52wk /ATL. And the daily is beyond into oversold! RSI 7= 7.91 and RSI 14=13.79! For those maybe not familiar? RSI 30 is considered OS territory. MACD has started to show signs of trying to go above giving us a golden cross. Will it? Possible. And one of my favorite indicators DPO. It also has started to curl upwards and fixin to try and cross into positive territory! I see all of these as good signs that it may be getting set to reverse? But theres the chance it says nope and drops lower? But i like it! Now lets talk dangerous part of swinging this. Looking at the chart we see that on 2/9 we close at 20.00! Then after the weekend, we open at 5.34! And Friday/yesterday 3/1 we hit that ATL ( bottom ) of 2.92! That crash was actually caused by the company itself! And im going to use the company’s own words here to explain.
(((((( On February 12, 2024, AN2 Therapeutics, Inc. (the “Company”) announced its decision to voluntarily pause Phase 3 enrollment in the Company’s seamless Phase 2/3 clinical trial (“EBO-301”) evaluating epetraborole in treatment-refractory Mycobacterium avium complex (“MAC”) lung disease, pending further data review. The double-blind, placebo-controlled trial has two arms comparing epetraborole plus optimized background regimen (“OBR”) versus placebo plus OBR. The voluntary pause was instituted following a blinded aggregate analysis of the ongoing Phase 2 study, including pooled patients from both treatment arms, which showed potentially lower than expected efficacy. The decision was not due to safety concerns. The Phase 2 part of the trial is intended to inform the Phase 3 part of the trial. The Company continues to expect to announce topline data from the Phase 2 part of the trial in summer 2024.
The Company’s decision to pause enrollment is expected to enable time to further evaluate study data and for the independent Data Safety Monitoring Board (the “DSMB”) to conduct an unblinded assessment and recommend next steps, which could include changes to the Phase 3 part of the study protocol. The Phase 2 part of the trial completed enrollment in September 2023 with 80 patients. The Phase 3 part of the trial has enrolled nearly 100 patients to date, a faster enrollment rate than previously anticipated. Patients already enrolled in the Phase 2/3 trial will be allowed to continue on study.
About the Epetraborole Pivotal Phase 2/3 Trial (EBO-301)
This double-blind, placebo-controlled superiority trial uses an adaptive design to evaluate the safety and efficacy of epetraborole in patients with treatment-refractory MAC lung disease. The Phase 2 part of the trial (n=80) assesses clinical response using various patient-reported outcome tools as well as the safety, efficacy, and pharmacokinetics of epetraborole plus an OBR, when compared to a placebo plus an OBR. The Phase 2 findings are expected to be utilized to inform the clinical response measures evaluated in the Phase 3 part of the trial and confirm the final sample size. The primary objective in Phase 3 (n=at least 234) will be to determine if epetraborole plus an OBR, consisting of two or more standard-of-care drugs, is superior to placebo plus an OBR. ))))))).
The Company’s decision to pause enrollment is expected to enable time to further evaluate study data and for the independent Data Safety Monitoring Board (the “DSMB”) to conduct an unblinded assessment and recommend next steps, which could include changes to the Phase 3 part of the study protocol. The Phase 2 part of the trial completed enrollment in September 2023 with 80 patients. The Phase 3 part of the trial has enrolled nearly 100 patients to date, a faster enrollment rate than previously anticipated. Patients already enrolled in the Phase 2/3 trial will be allowed to continue on study.
About the Epetraborole Pivotal Phase 2/3 Trial (EBO-301)
This double-blind, placebo-controlled superiority trial uses an adaptive design to evaluate the safety and efficacy of epetraborole in patients with treatment-refractory MAC lung disease. The Phase 2 part of the trial (n=80) assesses clinical response using various patient-reported outcome tools as well as the safety, efficacy, and pharmacokinetics of epetraborole plus an OBR, when compared to a placebo plus an OBR. The Phase 2 findings are expected to be utilized to inform the clinical response measures evaluated in the Phase 3 part of the trial and confirm the final sample size. The primary objective in Phase 3 (n=at least 234) will be to determine if epetraborole plus an OBR, consisting of two or more standard-of-care drugs, is superior to placebo plus an OBR. ))))))).
As you see they paused trial, not for safety reasons. But to examine data to make sure that this medication is / will be a better standard of care than existing treatments. But they have continued with patients already enrolled. That means they are still collecting data. And if they find that this trial will continue? They really haven’t lost much time with this pause. They are also still planning to present data from this study by / before mid year. And here is where i will bring in my OPINION! With how the earlier phases have gone, im betting that this trial will continue? And i could be totally wrong? Because advancing this far does not definitely mean that things haven’t taken a wrong turn with much more data collected! So in closing. Im going to start a swing position here mainly based on Technical / Charting! And if it gets a DCB? Well, i will sell for a profit! But if it decides to just accumulate at this level? Then i guess i will be accepting the dangerous part of this swing. And that is that i may be holding it when the news comes out on whether they terminate study? Which will cause IMO, another big drop in price. On the flip side. If / when they release data, if its good they will say they’re removing study pause and moving forward. Well if that happens? Then i believe this will start its march back towards opening price on 2/9/24.
I apologize if this is to long. But i have so many that ask me in PM how i find and decide some of my trades? So instead of trying to explain over and over. I figured i would take the time to show an example of some of the things that pique my interest. And explain my reasoning why! Right or wrong? This is some of what i look for. So here is 2 examples wrapped up in the same ticker of some things i look for in deciding if im interested enough to either watch for just a day trade. Or if im going to start a swing trade. So there you have it. Im not trying to explain a hypothetical. Im laying out in real time a real ticker. And how I decided on why im starting a position here! I want to REITERATE and make CLEAR! This is part of how i do it right or wrong? But it has worked well for me! I hope that it answers those of you who have been asking? And that anyone who reads this enjoys it! Feel free to comment! Even if you totally disagree! As long as your criticism is civil. I will engage in a conversation! Hope Y’all are having and will continue having a great weekend!![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
WarrenC : you're buying right now?
Super Waves : Are you buying now?
TrytosaveabitOP WarrenC: I plan on starting a position Monday PM yes! As I said in post. I will start scaling in a bit at a time.
TrytosaveabitOP Super Waves: Plan on it Monday PM to start scaling in a bit at a time!
Tarzanman : yes I'm in this waiting for them to restart trials this shud bounce back over 10 atlst
TrytosaveabitOP Tarzanman: My thoughts as well! But the danger is if they stop the trial! Price will plummet! GL and big profits to ya
Tarzanman TrytosaveabitOP: the CEO bought 1.5m shares down here if I'm not mistaken
Super Waves TrytosaveabitOP: Cool, Shifu, what is your target price for this one?
TrytosaveabitOP Tarzanman: Yes you’re correct! The number slips my mind right not! But sounds correct!
TrytosaveabitOP Super Waves: As always that depends on what happens! Since im swinging this, I don’t have a particular PT to the upside yet. But 5.13 would be where I would start thinking of scaling out? But that all depends on chart, volume and liquidity
View more comments...